Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Double blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A inhibitor) in Patients with an Acute Exacerbation of Schizophrenia

Next Previous
X
Search
Trial Profile

Phase II, Double blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore Efficacy, Safety and Pharmacokinetics of CPL500036 (PDE10A inhibitor) in Patients with an Acute Exacerbation of Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPL 500036 (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Celon Pharma

    • Most Recent Events

    • 09 Jul 2024 According to Celon Pharma media release, management plans to discuss encouraging results from this trial with regulatory agencies to advance CPL36 towards registrational trials and global marketing approvals
    • 09 Jul 2024 Primary endpoint (Change from baseline in PANSS positive subscale at Day 28.) has been met as per Celon Pharma media release
    • 09 Jul 2024 Results published in the Celon Pharma Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top